Aims-To study the expression of interleukin-2 receptor (IL-2R), interleukin-4 receptor (IL-4R) and interleukin-6 receptor (IL-6R) on peripheral blood lymphocytes (PBL) in patients with systemic lupus erythematosus (SLE); to correlate the level of expression of these receptors with SLE disease activity. Methods-Peripheral blood lymphocytes were studied by a high sensitivity flow cytometry technique using monoclonal antibodies directed against CD25 (IL-2R a chain), CD122 (IL-2R l chain), CD124 (IL-4R), and CD126 (IL-6R). SLE disease activity was scored using the SLE Disease Activity Index, C3 and C4 concentrations, anti-dsDNA level, and absolute lymphocyte count.
the CD122"'g (natural killer cell) population. The percentages of CD124+ and CD126+ PBLs in patients with SLE and controls were similar. On CD25+ cells, the relative antigenic level of the IL-2R a chain was significantly higher in patients with SLE (median 2.01 v 1.81). The relative antigenic levels of CD122+, CD124+ and CD126+ cells were similar in patients and controls. Neither the percentages nor the relative antigenic levels of all of these cytokine receptors were correlated with any of the parameters of disease activity.
Conclusion-Lymphocyte activation in patients with SLE was evident from the increase in CD25 expression on PBL, with a reciprocal decrease in CD122 expression. As the expression of IL-2R, IL-4R, IL-6R did not correlate with disease activity, it seems that these cytokinelreceptor systems do not play a direct role in disease activation in SLE. Systemic lupus erythematosus (SLE) is characterised by several functional abnormalities of the immune system, including impaired T cell responses and B cell hyper-reactivity. Abnormalities of the interleukin-2/interleukin-2 receptor (IL-2/IL-2R) system have been described previously in these patients-for example, increased serum concentrations of soluble IL-2R,'-' increased cellular expression of the Tac (CD25) antigen,6`8 and impaired production of IL-2 in vitro.27 Interleukin-4 (IL-4) and interleukin-6 (IL-6) were initially identified as B cell growth and differentiation factors. It is now known that the main physiological function of IL-4 is as a regulator of allergic diseases; IL-6 causes hepatocytes to synthesise several acute phase proteins. The role of IL-4 and IL-6 and their corresponding receptors in autoimmune diseases is not known but there is evidence suggesting these TH2 cytokines are involved in promoting and perpetuating B cell hyperactivity and autoantibody formation.9 In the present study, we sought to examine the expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes (PBL) of patients with SLE in comparison with normal individuals, using a sensitive immunofluorescence technique that detects low antigenic expression generally missed on conventional staining. The expression of these receptors on PBL was correlated with SLE disease activity. To measure disease activity, we have chosen the SLE Disease Activity Index (SLEDAI)' which consists of 24 weighted clinical and laboratory parameters. Other markers of SLE disease activity, including C3, anti-dsDNA, and the absolute lymphocyte count were also measured for comparison.
Methods
Sixty nine (eight men) consecutive patients from the Department of Medicine, University of Hong Kong, who met four or more of the criteria of the American College of Rheumatology for the classification of SLE, were studied." At the time of study, all patients were receiving no more than 15 mg prednisolone; some were also taking 50-100 mg azathioprine. There was no difference in drug treatment between the patients with active and inactive disease because the former were studied prior to the augmentation of their steroid Tables 1 and 2 show the medians, first and third quartiles of CD25, CD122, CD124, and CD126 expression on PBL in patients with SLE and normal controls. Representative staining patterns of these cytokine receptors are shown in fig 1. The percentage of PBL that were CD25+ was significantly higher in patients with SLE than in controls (p < 0.001). The relative density of CD25 molecules on CD25+ PBL, as indicated by the mean channel number of fluorescent cells, was also significantly higher in patients with SLE (p < 0.05). Expression of CD25 was similar in controls and patients with active disease (SLEDAI > 9). However, expression of CD25 in those with inactive disease (SLEDAI < 5) was significantly higher than in normal controls (p < 0.01).
Conversely, a significantly greater proportion of PBL in normal controls were CD 122+ than in patients with SLE (p < 0.05). Those patients with inactive disease (SLEDAI < 5) had a significantly lower percentage of CD122+ PBL than normal controls (p < 0.05). The difference between patients with active disease (SLEDAI > 9) and normal controls was not statistically significant ( controls. Furthermore, CD4+CD29+ T cells, which were the major T cells producing IL-6, were also increased in the circulation of patients with SLE.'5 It is postulated that overexpression of these cytokines may contribute to the B cell hyperactivity and enhanced antibody synthesis characteristic of this autoimmune disease. In the present study, the level of expression of IL-4R and IL-6R on PBL of patients with SLE was no different from that in normal subjects. It would be interesting to know whether there is any difference in expression of these receptors on T, B and other lymphocyte subsets. Nagafuchi et af4 reported overexpression of IL-6R on B lymphocytes of patients with SLE. Further study on these cytokines and cytokine receptors should help to delineate the immunological abnormalities in SLE.
